Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death.

The Myc oncoprotein dimerizes with its partner, Max, to bind DNA, activate transcription, and promote cell proliferation, as well as programmed cell death. Max also forms homodimers or heterodimers with its alternative partners, Mad and Mxi-1. These complexes behave as antagonists of Myc/Max through competition for common DNA targets, and perhaps permit cellular differentiation.

[1]  C. Dang,et al.  Max: functional domains and interaction with c-Myc. , 1992, Genes & development.

[2]  G. Prendergast,et al.  A new bind for Myc. , 1992, Trends in genetics : TIG.

[3]  P. Leder,et al.  An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence. , 1992, Genes & development.

[4]  M. Cole,et al.  Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. , 1992, Genes & development.

[5]  M. Birrer,et al.  Regions within the c-Myc protein that are necessary for transformation are also required for inhibition of differentiation of murine erythroleukemia cells. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  G. Evan,et al.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.

[7]  V. Rotter,et al.  c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[8]  R. DePinho,et al.  Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. , 1992, Genes & development.

[9]  Bruno Amati,et al.  Oncogenic activity of the c-Myc protein requires dimerization with Max , 1993, Cell.

[10]  M. Pagano,et al.  Differential modulation of cyclin gene expression by MYC. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  N. Hay,et al.  c-Myc induces the expression and activity of ornithine decarboxylase. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[12]  M. Raffeld,et al.  Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. , 1993, Oncogene.

[13]  G. Klein,et al.  Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. , 1993, Oncogene.

[14]  G. Evan,et al.  Domains of human c-myc protein required for autosuppression and cooperation with ras oncogenes are overlapping , 1990, Molecular and cellular biology.

[15]  A. Rustgi,et al.  Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product , 1991, Nature.

[16]  A. Patel,et al.  myc function and regulation. , 1992, Annual review of biochemistry.

[17]  E. Reddy,et al.  Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation. , 1992, Oncogene.

[18]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[19]  Stephen K. Burley,et al.  Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain , 1993, Nature.

[20]  V. Pirrotta,et al.  Multimerization of the Drosophila zeste protein is required for efficient DNA binding. , 1993, The EMBO journal.

[21]  M. Cole,et al.  max encodes a sequence-specific DNA-binding protein and is not regulated by serum growth factors. , 1992, Oncogene.

[22]  J A Moshier,et al.  Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. , 1993, Cancer research.

[23]  W. Gu,et al.  Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Andersson,et al.  Ornithine decarboxylase activity is critical for cell transformation , 1992, Nature.

[25]  M. Henriksson,et al.  Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers. , 1993, Oncogene.

[26]  D. Gillespie,et al.  Transcription activation by Myc and Max: flanking sequences target activation to a subset of CACGTG motifs in vivo. , 1993, The EMBO journal.

[27]  B. Amati,et al.  Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. , 1993, Nucleic acids research.

[28]  G. Evan,et al.  Max and c-Myc/Max DNA-binding activities in cell extracts. , 1992, Oncogene.

[29]  J. Woodgett,et al.  Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. , 1994, Oncogene.

[30]  K. Alitalo,et al.  Alternative Forms of Max as Enhancers or Suppressors of Myc-Ras Cotransformation , 1992, Science.

[31]  K. Klempnauer,et al.  Sequence-specific DNA binding by Myc proteins. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. DePinho,et al.  Myc and Max: a putative transcriptional complex in search of a cellular target. , 1992, Current opinion in cell biology.

[33]  R. Eisenman,et al.  Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.

[34]  R. Davis,et al.  Cell cycle regulation of the c-Myc transcriptional activation domain , 1993, Molecular and cellular biology.

[35]  R. Brent,et al.  Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites , 1993, Cell.

[36]  H. Varmus,et al.  Definition of regions in human c-myc that are involved in transformation and nuclear localization , 1987, Molecular and cellular biology.

[37]  C. Goding,et al.  C-myc and the yeast transcription factor PHO4 share a common CACGTG-binding motif. , 1991, Oncogene.

[38]  M. Obinata,et al.  Functional domains of c-Myc involved in the commitment and differentiation of murine erythroleukemia cells. , 1993, Oncogene.

[39]  D. Gillespie,et al.  Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity. , 1993, Oncogene.

[40]  R. Eisenman,et al.  Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity , 1993, Cell.

[41]  R. Eisenman,et al.  Myc and Max associate in vivo. , 1992, Genes & development.

[42]  H. Weintraub,et al.  Sequence-specific DNA binding by the c-Myc protein. , 1990, Science.

[43]  G. Prendergast,et al.  Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation , 1991, Cell.

[44]  S. Goff,et al.  Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc. , 1993, Science.

[45]  G. Evan,et al.  The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. , 1993, The EMBO journal.

[46]  H. Hibshoosh,et al.  Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation. , 1991, Oncogene.

[47]  R. Eisenman,et al.  A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. , 1993, Genes & development.

[48]  C. Dang,et al.  Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells , 1992, Molecular and cellular biology.

[49]  R. Roeder,et al.  Direct role for Myc in transcription initiation mediated by interactions with TFII-I , 1993, Nature.

[50]  I. Magrath,et al.  Point mutations in the c–Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas , 1993, Nature Genetics.

[51]  G. Prendergast,et al.  Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. , 1991, Science.

[52]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[53]  M. Mori,et al.  Prothymosin-α mRNA expression correlates with that of c-myc in human colon cancer , 1993 .

[54]  D. Gillespie,et al.  The leucine zipper domain of avian cMyc is required for transformation and autoregulation. , 1990, Oncogene.

[55]  C. Dang,et al.  B-myc inhibits neoplastic transformation and transcriptional activation by c-myc , 1993, Molecular and cellular biology.

[56]  J. Lautenberger,et al.  Sequence curiosity in v-myc oncogene , 1985, Nature.

[57]  L. J. Veer,et al.  TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[58]  L. Larsson,et al.  Expression of mad, mxi1, max and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. , 1994, Oncogene.

[59]  N. Hay,et al.  Sequence-specific transcriptional activation by Myc and repression by Max , 1993, Molecular and cellular biology.

[60]  T. Graf,et al.  The transforming activity of the chicken c-myc gene can be potentiated by mutations. , 1987, Oncogene.

[61]  G. Prendergast,et al.  Biphasic effect of Max on Myc cotransformation activity and dependence on amino- and carboxy-terminal Max functions. , 1992, Genes & development.

[62]  M. Schwab,et al.  The N‐Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. , 1991, The EMBO journal.

[63]  A. Baxevanis,et al.  Interactions of coiled coils in transcription factors: where is the specificity? , 1993, Current opinion in genetics & development.

[64]  J. Bishop,et al.  The MYC protein activates transcription of the alpha‐prothymosin gene. , 1991, The EMBO journal.

[65]  J. Barrett,et al.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.

[66]  G. Evan,et al.  The role of c-myc in cell growth. , 1993, Current opinion in genetics & development.